

Vision Improvement with Combination Low-fluence Photodynamic Therapy (LFPDT) and Intravitreal Injection

Gregory R. Blaha, MD, PhD (Peabody, MA), Jeffrey L. Marx, MD (Peabody, MA)*

PURPOSE

To report our experience with combination low-fluence PDT.

METHODS

An IRB-approved, retrospective chart review of all patients receiving low-fluence (50% standard) PDT (LFPDT) at our institution was performed.

RESULTS

Twenty five eyes of 24 patients received LFPDT. Two eyes did not receive combination therapy, two received Macugen (Pegaptanib, OSI/Eyetech) and 21 eyes received intravitreal triamcinolone acetonide (4mg). Vision was maintained within three lines or improved in 24 of 25 eyes. Five patients had improved vision of three lines or more (four involving triamcinolone and one with Macugen) with a median of 5 months follow-up. OCT frequently showed resolution of fluid. Three patients required subsequent anti-VEGF treatment. Side effects were low and no patient had profound hypoperfusion.

CONCLUSION

Combination low-fluence PDT and intravitreal injection therapy can lead to vision improvement and may have decreased side-effects compared to combination therapy with standard PDT. LFPDT may be a useful adjunct to anti-VEGF treatment.